Human Genome Sciences And Lonza Enter Commercial Manufacturing Agreement For BENLYSTA(R), A Potential New Treatment For Systemic Lupus Erythematosus

Links shared publicly online about this topic.

  • 1,020
    total visits

Human Genome Sciences And Lonza Enter Commercial Manufacturing Agreement For BENLYSTA(R), A Potential New Treatment For Systemic Lupus Erythematosus

medicalnewstoday.com —

Human Genome Sciences, Inc. (Nasdaq:HGSI) and Lonza announced an agreement for the future commercial supply of BENLYSTA® (belimumab), which is currently under regulatory review in the United S

View full resource at medicalnewstoday.com

Tags: Lupus, Systemic Lupus Erythematosus

  • Share

Most Recently Shared on July 15, 2010 at 5:06 pm By:

mnt_lupus MNT Lupus News

Human Genome Sciences And Lonza Enter Commercial Manufacturing Agreement For BENLYSTA(R), A Potential New Treatment Fo... http://mnt.to/3G6X

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

Health Line Health Line

Advertisement